- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04190329
Feasibility of an Extended Test Battery and Influencing Factors for Detecting Frailty
7. oktober 2020 opdateret af: Claudia Spies, Charite University, Berlin, Germany
The aim of the prospective study is to assess the feasibility of a screening and baseline measurement protocol that is planned for a main study (PRÄP-GO) in a collective of 30 patients ageing 70+ scheduled for elective surgery.
Comprehensive geriatric assessment scores and modified Fried frailty phenotype component evaluation are performed in all patients at baseline before elective surgery.
The assessment of cognitive tests is conducted with a battery of neuropsychological tests, computer-based tests from the Cambridge Neuropsychological Test Automated Battery [CANTAB®] and non-computer based tests.
Frailty scores from 0 to 5 (i.e., 1 point for each component; 0 = best to 5 = worst) represent robust (0), pre-frail (1-2), and frail (3-5) health status. 10 patients without Frailty, 10 patients with Pre-Frailty and 10 patients with Frailty should be analyzed in this study and receive further comprehensive geriatric assessment testing up to seven days after surgery/discharge (before 7 postoperative days).
Studieoversigt
Status
Afsluttet
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Faktiske)
30
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
-
Berlin, Tyskland, 13353
- Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité - Universitätsmedizin Berlin
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
70 år og ældre (Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Patients undergoing elective surgery aged ≥70 years, including 10 patients without Frailty, 10 patients with Pre-Frailty and 10 patients with Frailty.
Beskrivelse
Inclusion criteria:
- Age ≥ 70 years
- Male and female patients
- Patient eligible for inclusion: by the patient, preoperatively
- elective surgery
- Expected anesthesia duration> 60min
Exclusion criteria:
- Severe cardiological or pulmonary disease (NYHA IV, Gold IV)
- Intracranial interventions
- Moribund patients (palliative situation)
- Not enough language skills
- Non-consenting patients
- Participation in another prospective intervention study for study inclusion or throughout the study period.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
10 non-frail (robust) study patients
Patients fulfill 0 criteria according to modified Fried frailty score.
|
|
10 pre-frail study patients
Patients fulfill 1-2 criteria criteria according to modified Fried frailty score.
|
|
10 frail study patients
Patients fulfill 3, 4 or 5 criteria according to modified Fried frailty score.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration to run the test battery
Tidsramme: 1 day (Once only at screening)
|
The duration of the screening test battery is measured with a stopwatch.
|
1 day (Once only at screening)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Acceptance of test battery
Tidsramme: 1 day (Once only at screening)
|
The study patient´s acceptance of the screening test battery is measured with a questionnaire.
|
1 day (Once only at screening)
|
|
Problems to conduct the test battery
Tidsramme: 1 day (Once only at screening)
|
Problems while performing the test battery are categorized according to a standardized protocol.
|
1 day (Once only at screening)
|
|
Change in pain
Tidsramme: Baseline, day 3 after surgery and discharge or day 7 after surgery
|
Pain is measured with a pain score, a higher score indicates more pain.
|
Baseline, day 3 after surgery and discharge or day 7 after surgery
|
|
Intelligibility of the patient Diary 1
Tidsramme: Up to day 7 after surgery
|
Number of completed items
|
Up to day 7 after surgery
|
|
Intelligibility of the patient Diary 2
Tidsramme: Up to day 7 after surgery
|
Number of completed days
|
Up to day 7 after surgery
|
|
Intelligibility of the patient Diary 3
Tidsramme: Up to day 7 after surgery
|
Coherence of the diary with clinical patient record
|
Up to day 7 after surgery
|
|
Implementation rate of the patient Diary 3
Tidsramme: Up to day 7 after surgery
|
Up to day 7 after surgery
|
|
|
Handgrip strength
Tidsramme: Baseline, day 3 after surgery and discharge or day 7 after surgery
|
Handgrip strength measured using a Dynamometer.
|
Baseline, day 3 after surgery and discharge or day 7 after surgery
|
|
Mobility
Tidsramme: Baseline, day 3 after the operation and discharge or day 7 after surgery
|
Mobility is measured using the Charité Mobilitäts-Index (CHARMI®).
|
Baseline, day 3 after the operation and discharge or day 7 after surgery
|
|
Nutritional status 1
Tidsramme: Baseline and discharge or day 7 after surgery
|
Nutritional status 1 is measured using serum albumin.
|
Baseline and discharge or day 7 after surgery
|
|
Nutritional status 2
Tidsramme: Baseline and discharge or day 7 after surgery
|
Nutritional status 2 is measured using arm circumference.
|
Baseline and discharge or day 7 after surgery
|
|
Nutritional status 3
Tidsramme: Baseline and discharge or day 7 after surgery
|
Nutritional status 3 is measured using calf circumference.
|
Baseline and discharge or day 7 after surgery
|
|
Nutritional status 4
Tidsramme: Baseline and discharge or day 7 after surgery
|
Nutritional status 4 is measured using the Mini Nutritional Assessment - Short Form (MNA®-SF).
|
Baseline and discharge or day 7 after surgery
|
|
Intra- and postoperative organ complications
Tidsramme: Up to 7 days after surgery
|
Up to 7 days after surgery
|
|
|
Length of intensive care unit stay
Tidsramme: Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
Participants will be followed for the duration of hospital stay, an expected average of 1 day.
|
|
|
Length of stay
Tidsramme: Participants will be followed for the duration of hospital stay, an expected average of 7 days.
|
Participants will be followed for the duration of hospital stay, an expected average of 7 days.
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cognitive Status
Tidsramme: 1 day (Once only at screening)
|
Neuropsychological testing
|
1 day (Once only at screening)
|
|
Depression
Tidsramme: 1 day (Once only at screening)
|
The assessment of Depression is measured with the - Patient Health Questionnaire (PHQ-8)
|
1 day (Once only at screening)
|
|
Frailty
Tidsramme: 1 day (Once only at screening)
|
Frailty is operationalized using modified Fried frailty criteria.
Frailty scores from 0 to 5 (i.e., 1 point for each component; 0 = best to 5 = worst) represent robust (0), pre-frail (1-2), and frail (3-5) health status.
|
1 day (Once only at screening)
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Studieleder: Claudia Spies, MD Prof., Department of Anesthesiology and Operative Intensive Care Medicine (CCM/CVK), Charité Univerisitätsmedizin Berlin
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
18. december 2019
Primær færdiggørelse (Faktiske)
16. juli 2020
Studieafslutning (Faktiske)
20. juli 2020
Datoer for studieregistrering
Først indsendt
28. november 2019
Først indsendt, der opfyldte QC-kriterier
4. december 2019
Først opslået (Faktiske)
9. december 2019
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
8. oktober 2020
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
7. oktober 2020
Sidst verificeret
1. oktober 2020
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- Frailty-Testing
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Skrøbelighedssyndrom
-
GlaxoSmithKlineIkke rekrutterer endnu
-
Unravel Biosciences, Inc.RekrutteringPitt Hopkins syndromColombia
-
Helen Keller Eye Research FoundationFive Lakes Clinical Research Consulting, LLCRekrutteringStickler syndrom type 2 | Stickler syndrom type 1Forenede Stater
-
University of California, Los AngelesBoston Children's Hospital; Duke University; Children's Hospital Medical...RekrutteringBohring-Opitz syndrom | ASXL1 genmutation | Shashi-Pena syndrom | ASXL2-genmutation | Bainbridge-Ropers syndrom | ASXL3 genmutationForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
University of California, DavisNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AfsluttetTidligere behandlet myelodysplastisk syndrom | Myelodysplastisk syndrom | Terapi-relateret myelodysplastisk syndrom | Sekundært myelodysplastisk syndrom | Refraktært højrisiko myelodysplastisk syndromForenede Stater
-
Neuren Pharmaceuticals LimitedRekrutteringPhelan-McDermid syndromForenede Stater
-
Riphah International UniversityAfsluttet
-
Riphah International UniversityAfsluttet
-
Shaare Zedek Medical CenterUkendtPræmenstruelt syndrom - PMS